DOI: 10.1002/gps.5810

RESEARCH ARTICLE

Geriatric Psychiatry WILEY

Delirium in older COVID-19 patients: Evaluating risk factors and outcomes

Bart Kroon¹ Sara J. E. Beishuizen² | Inge H. T. van Rensen³ | Dennis G. Barten³ | Jannet J. Mehagnoul-Schipper⁴ | Jessica M. van der Bol⁵ | Jacobien L. J. Ellerbroek⁵ | Jan Festen⁶ | Esther M. M. van de Glind⁷ | Liesbeth Hempenius⁸ | Mathieu van der Jagt⁹ | Steffy W. M. Jansen¹⁰ | Carolien J. M. van der Linden¹⁰ | Simon P. Mooijaart¹¹ | Barbara C. van Munster¹² | Leanne L. E. Oosterwijk¹ | Lisa Smit⁹ | Louise C. Urlings-Strop¹³ | Hanna C. Willems¹⁴ | Francesco U. S. Mattace-Raso¹ | Harmke A. Polinder-Bos¹

¹Department of Geriatric Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands

²Department of Geriatric Medicine, OLVG Hospitals Amsterdam, Amsterdam, The Netherlands

³Department of Emergency Medicine, VieCuri Medical Center, Venlo, The Netherlands

⁴Intensive Care Department, VieCuri Medical Center, Venlo, The Netherlands

⁵Department of Geriatric Medicine, Reinier de Graaf Hospital, Delft, The Netherlands

⁶KBO-PCOB, Nieuwegein, The Netherlands

⁷Department of Geriatric Medicine, Alrijne Hospital, Leiderdorp, The Netherlands

⁸Department of Geriatric Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands

⁹Intensive Care Department, Erasmus Medical Center, Rotterdam, The Netherlands

¹⁰Department of Geriatric Medicine, Catharina Hospital, Eindhoven, The Netherlands

¹¹Department of Gerontology and Geriatrics, LUMC, Leiden, The Netherlands

¹²Department of Geriatric Medicine, UMCG, Groningen, The Netherlands

¹³Intensive Care Department, Reinier de Graaf Hospital, Delft, The Netherlands

Abstract

Objectives: A high incidence of delirium has been reported in older patients with Coronavirus disease 2019 (COVID-19). We aimed to identify determinants of delirium, including the Clinical Frailty Scale, in hospitalized older patients with COVID-19. Furthermore, we aimed to study the association of delirium independent of frailty with in-hospital outcomes in older COVID-19 patients.

Methods: This study was performed within the framework of the multi-center COVID-OLD cohort study and included patients aged ≥ 60 years who were admitted to the general ward because of COVID-19 in the Netherlands between February and May 2020. Data were collected on demographics, co-morbidity, disease severity, and geriatric parameters. Prevalence of delirium during hospital admission was recorded based on delirium screening using the Delirium Observation Screening Scale (DOSS) which was scored three times daily. A DOSS score ≥ 3 was followed by a delirium assessment by the ward physician In-hospital outcomes included length of stay, discharge destination, and mortality.

Results: A total of 412 patients were included (median age 76, 58% male). Delirium was present in 82 patients. In multivariable analysis, previous episode of delirium (Odds ratio [OR] 8.9 [95% CI 2.3–33.6] p = 0.001), and pre-existent memory problems (OR 7.6 [95% CI 3.1–22.5] p < 0.001) were associated with increased delirium risk. Clinical Frailty Scale was associated with increased delirium risk (OR 1.63 [95%CI 1.40–1.90] p < 0.001) in univariable analysis, but not in multivariable analysis. Patients who developed delirium had a shorter symptom duration and lower levels of C-reactive protein upon presentation, whereas vital parameters did

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.

¹⁴Department of Internal Medicine and Geriatrics, Amsterdam University Medical Centers, Amsterdam, The Netherlands

Correspondence

Bart Kroon, Department of Geriatric Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands. Email: b.kroon@erasmusmc.nl

Funding information

Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Zorg Onderzoek Nederland en Medische Wetenschappen not differ. Patients who developed a delirium had a longer hospital stay and were more often discharged to a nursing home. Delirium was associated with mortality (OR 2.84 [95% CI1.71–4.72] p < 0.001), but not in multivariable analyses.

Conclusions: A previous delirium and pre-existent memory problems were associated with delirium risk in COVID-19. Delirium was not an independent predictor of mortality after adjustment for frailty.

KEYWORDS

CFS, COVID-19, delirium, mortality

Key points

- A previous episode of delirium and pre-existent memory problems were independent predictors of delirium risk in older adults hospitalized with COVID-19.
- Reports on the association of delirium with poor outcomes, independent of frailty, in older hospitalized COVID-19 patients have been conflicting.
- In this study, delirium was not a predictor of in-hospital mortality independent of frailty.

1 | INTRODUCTION

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a high burden on global healthcare, and older patients are particularly affected.¹⁻³ COVID-19 typically presents as a respiratory infection, with cough, dyspnea and fever as the most prevalent acute symptoms.^{4,5} In older people, COVID-19 may present more atypically, with delirium being an established way of presentation.⁶ In general, delirium is a manifestation of severe disease in older patients, and previously described as a risk factor for morbidity and mortality.^{7,8}

An incidence of delirium between 14% and 40% has been reported in patients admitted because of COVID-19 at the general ward.⁹⁻¹¹ Traditional predisposing determinants of delirium in hospitalized patients are well-known, and include cognitive impairment and dementia, advanced age, a history of delirium, dependency in activities of daily living (ADL) and comorbidity.¹²⁻¹⁵ We hypothesize that these risk factors are also associated with delirium in older adults hospitalized with COVID-19. Furthermore, a higher level of frailty was associated with higher delirium prevalence in COVID-19 patients at the general ward and Intensive Care Unit (ICU).^{16,17} It remains to be investigated whether frailty, according the Clinical Frailty Scale (CFS), is also a determinant of delirium in COVID-19 independent of the traditional predisposing delirium determinants.

The CFS, used in 80% of COVID-19 literature as a frailty measure, has emerged as an established predictor of in-hospital mortality in older patients admitted with COVID-19.^{18,19} Similar to the CFS score, delirium has also been associated with mortality in older COVID-19 patients. A recent study reported a pooled mortality rate of 45% in patients admitted with COVID-19 who developed delirium, compared to 22% in patients who did not develop a delirium.²⁰ Whether delirium and frailty are both independent predictors of mortality, or if frailty explains the association of delirium with mortality is debatable. Conflicting findings have been reported, suggesting that delirium predicts

mortality independent from frailty,²¹⁻²³ and studies that suggest no association of delirium with mortality.^{19,24}

The aim of this study was to investigate whether traditional predisposing determinants and the CFS are associated with delirium in older COVID-19 patients admitted and hospitalized at the general ward. Second, this study aimed to evaluate whether delirium was a predictor of in-hospital mortality independent of frailty in older COVID-19 patients.

2 | METHODS

2.1 | Study design

This was a multicenter cohort study among patients aged 60 years and older hospitalized at the general ward because of COVID-19 from February to May 2020 in the Netherlands, as a substudy of the 'COVID-OLD' study. Data were collected from six Dutch hospitals: Alrijne hospital, Erasmus Medical Center, Medical Center Leeuwarden, Reinier de Graaf Hospital, University Medical Center Groningen and VieCuri Medical Center. An opt-out procedure was used to include eligible patients, which means chart data were available for scientific research unless a patient explicitly objected. The medical ethics committees of all hospitals waived the necessity for formal approval of the study, as data collection followed routine practice. We excluded patients admitted to the ICU due to a large number of missing data and due to inter hospital differences in sedation protocols leading to difficulties in assessing and comparing delirium scores.

2.2 | Study participants

The inclusion criteria were age \geq 60 years and hospitalization with diagnosed COVID-19 infection. Patients who were transferred to

another hospital were not included because information regarding delirium post-transfer was lacking. Furthermore, patients admitted to the hospital for <24 h and patients admitted to the ICU were excluded.

2.3 | Data collection

Demographic, clinical, laboratory data (creatinine using enzymatic analysis and C-reactive protein (CRP) using turbimetric analysis) at baseline (i.e., the first day of admission), and outcome data were collected from the electronic medical records. Risk factors for delirium were extracted from the medical records using the Dutch National Safety Management System (VMS). This risk assessment tool consists of 13 questions regarding four geriatric domains: physical impairment, risk of falls, delirium, self-reported cognitive impairment and malnutrition.²⁵ Comorbidities were listed using the Charlson Comorbidity Index (CCI).²⁶ Predisposing delirium factors were age, comorbidities, frailty, a previous episodes of delirium during hospitalization, a history of cognitive problems, and dependency in ADL.¹⁴ Dependency in ADL was assessed using the Katzscore, which ranges from 0 to 6, with 0 meaning completely independent and 6 completely dependent on caregivers.²⁷ The CFS has been developed by Rockwood et al.²⁸ and consists of a nine-point scale varying from 1 (very fit) to 9 (terminally ill). The CFS was prospectively assigned during the first day of hospital admission and noted in the medical record. If not prospectively assigned, the CFS was determined retrospectively based on available chart data about pre-morbid functional status 2 weeks before admission, and was scored by a geriatrician or internist-geriatrician, or researcher trained by a geriatrician or internist-geriatrician.

2.4 | Definitions and outcomes

Prevalence of delirium during hospital admission was recorded at the general ward based on delirium screening using the Delirium Observation Screening Scale (DOSS) which was scored three times daily. The DOSS score is a widely used delirium screening tool that shows good validity and reliability.²⁹ DOSS score \geq 3 suggesting a delirium was followed by a delirium assessment by the ward physician according to a clinical assessment based on the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria.

2.5 | Statistical analysis

Demographics and clinical variables were summarized using descriptive statistics. Baseline differences between patients with and without delirium were assessed with independent *T* test, or Mann-Whitney U test, as appropriate. A *p*-value <0.05 was considered statistically significant. Predisposing determinants of delirium were prespecified, and included age, a previous episode of delirium,

previous memory problems, ADL dependency, comorbidity burden according the Charlson Comorbidity Index, a fall in the last 6 months, and frailty according the CFS.

The association between determinants of delirium was first assessed with univariate logistic regression. All determinants were added in one multivariate logistic regression model including sex, and with delirium as outcome variable. Multicollinearity in the multivariable models was checked by calculating the variance inflation factor (VIF) of all variables. Differences regarding in-hospital outcomes in patients with and without delirium were assessed with independent t test, or Mann-Whitney U test, as appropriate. The association of delirium with in-hospital mortality, and of CFS score with in-hospital mortality, was first evaluated using univariate logistic regression. Next, all associated risk factors were added in one multivariate logistic regression model with in-hospital mortality as outcome variable.

Data were collected using Castor Electronic Data Capture (Amsterdam, The Netherlands). Statistical analyses were performed using International Business Machines Corporation (IBM) Statistical Package for the Social Sciences Statistics, version 25 (IBM Corp., Armonk, NY, USA).

3 | RESULTS

3.1 | Enrollment

A total of 558 patients aged \geq 60 years were hospitalized with COVID-19 in the participating hospitals during the study period. 146 (26%) patients were excluded because of incomplete data due to transfers to other hospitals, admission to the ICU and hospital stay of <24 h resulting in a cohort of 412 patients (Figure 1).

3.2 | Baseline characteristics

Baseline characteristics of the 412 patients are shown in Table 1. The median age was 76 years (interquartile range [IQR] 68–82), and 57.8% was male. Clinical Frailty Scale data were collected in 325 (78.9%) patients. In total, 180 (55.4%) patients were classified as CFS 1–3, 66 (20.3%) patients as CFS 4–5, and 79 (24.3%) patients as CFS 6–9. Pre-existent memory problems were in 66 (18.9%) patients, and 86 (29.2) patients experienced a fall in the last six months before hospital admission.

3.3 | Delirium and risk factors

Delirium was present in 82 (20%) patients during hospitalization. Table 1 also shows baseline characteristics stratified for delirium during presentation. Patients who developed a delirium were older (82 years [IQR 77-86] vs. 74 [IQR 67-81], p < 0.001), had more ADL dependencies (median Katz-Activities of daily living score 3 [IQR 0-



FIGURE 1 Flowchart of study population

6] vs. 0 [IQR 0–2], p < 0.001), were more likely to have had a previous episode of delirium (45.3% vs. 3.6%, p < 0.001), and a history of memory problems (62% vs. 7.9%, p < 0.001). Patients with a delirium had a higher CFS score (6 [IQR 4–7]) compared to patients who did not develop a delirium during hospital admission (3 [IQR 2–5], p < 0.001). Furthermore, patients who developed a delirium were more likely to have experienced a fall in the last 6 months before hospital admission (55.9% vs. 21.1%, p < 0.001). Vital parameters at admission did not differ between patients with and without a delirium. Patients who developed a delirium had lower CRP levels at admission (70 [IQR 35–119] vs. 89 [IQR 40–152] mg/L p = 0.04), a higher creatinine level at admission (98 [IQR 75–134] vs. 87 [71–118] µmol/L, p = 0.02), and a shorter duration of symptoms preadmission (5 [IQR 3–8] vs. 7 [4–11] days p = 0.002).

Univariable and multivariable associations of predisposing determinants of delirium are shown in Table 2. Older age, higher CCI, higher number of ADL dependencies, a previous fall, and a higher CFS score were all associated with delirium in the crude model, but not after adjustment in the multivariable model. A previous episode of delirium was both univariable (Odds ratio [OR] 22.5 [95% CI 9.5– 53.1], p < 0.001) and multivariable (OR 9.4 [95% CI 3.1–28.6] p < 0.001) associated with delirium risk. Furthermore, pre-existent memory problems was both univariable (OR 6.1 [95% CI 9.9– 36.2], p < 0.001) and multivariable (OR 6.1 [95% CI 2.7–13.9] p < 0.001) associated with delirium risk as well. The VIF of all variables was <2.2, indicating no multicollinearity in this model.

3.4 | In-hospital outcomes

The associations between delirium and in-hospital outcomes are listed in Table 3. The median length of stay was longer in patients who developed a delirium versus patients without a delirium (median 8 [IQR 5–13] vs. 6 [IQR 3–10] days, p = 0.002). Patients who developed a delirium were more frequently discharged to a nursing home

(35.6% vs. 15.2%, p = 0.001). A total of 111 (26.9%) patients died during hospitalization, and in-hospital mortality was higher in patients with a delirium when compared to patients without delirium (45.1% vs. 22.4%, p = 0.03) (Table 4).

In univariate analysis, older age (OR 1.09 [95% CI 1.06–1.12] p < 0.001), a delirium (OR 2.84 [95% CI 1.71–4.72] p < 0.001), a higher Charlson Comorbidity Index (OR 1.22 [95% CI 1.09–1.36] p < 0.001) and a higher CFS score (OR 1.48 [95% CI 1.29–1.70] p < 0.001) were all associated with in-hospital mortality. In multivariate analysis, older age (OR 1.04 [95% CI 1.01–1.08] p = 0.012) and a higher CFS (OR 1.42 [95% CI 1.21–1.67] p < 0.001) were associated with in hospital mortality, whereas delirium was not.

4 | DISCUSSION

In this multicenter cohort study we found that a previous episode of delirium and the presence of cognitive impairment were independently associated with delirium in patients admitted to the hospital with a COVID-19 infection. The association of delirium with inhospital mortality disappeared after multivariable adjustment.

We found a delirium prevalence of 20% in our study population, which is somewhat lower than the prevalence described in previous COVID-19 studies of 14%-40%.⁹⁻¹¹ This may be explained by the fact that we included patients aged 60 and older, while some other studies included older patients leading to a higher delirium prevalence. Furthermore, we excluded patients who were transferred to the ICU, which is a population with very high delirium risk.³⁰ Our findings on predisposing determinants of delirium are partially in line with a recent study describing delirium risk factors in older COVID-19 patients who were ineligible for intensive care admission.³¹ In this study by Mendes et al., only cognitive impairment was associated with a higher risk of delirium. Other risk factors such as previous delirium and ADL (in)dependency were not studied. Another recent study of Rebora et al. describes dementia, a higher number of chronic diseases and opacities on chest X-ray or CT as predictors for delirium. They also did not study a previous delirium episode as a risk factor, which is known to be a very strong predictor for delirium.^{11,14} Frailty is an established risk factor for delirium across different populations of non-COVID hospitalized patients.³² In the COVID population, a recent review and meta-analysis found that frailty. based on the CFS, was associated with increased delirium risk (OR 2.91; 95% CI 2.00-4.25).¹⁷ However, these were all unadjusted associations. We found a similar increased delirium risk in frail patients in our univariable analyses. However, when taking into account other predisposing delirium risk factors, frailty was not independently associated with delirium risk. A previous episode of delirium and preexisting memory problems were independent determinants of an increased delirium risk. Few previous studies investigated the impact of frailty together with other predisposing risk factors on delirium prevalence in COVID-19 patients. First, in two cohorts, a CFS >5 was associated with increased delirium risk.^{10,22} Second, in a large multicenter study, increased CFS was not associated with incident

TABLE 1 Baseline characteristics of older patients hospitalized with COVID-19 stratified by the presence of delirium

N = 412 N = 300 N = 82 p-value Patient: N = 422 N = 300 N = 82 p-value Patient: durancteristics A 82 (77-80) 6.0001 Male (N) 238 (57.8%) 191 (57.9%) 47 (57.3%) 0.93 Body Mass index (kg/m ⁷) 2.62 (23.9-29.2) 2.63 (23.2-29.1) 0.64 Living situation before admission 2.62 (23.9-29.2) 2.63 (24.2-29.1) 0.64 Living situation before admission 2.62 (23.9-29.2) 2.63 (23.2-29.1) 0.64 Call -3 3.63 (92.1%) 2.64 (24.2-29.1) 0.60.73 Call -4 2.65 (90.3%) 10 (17.3%) 7.65 Call -5 2.64 (93.9%) 10 (30%) 2.(2.6%) Call -4 7.4 (18.0%) 55 (16.7%) 19 (19.1%) Call -5 1.80 (55.4%) 1.05 (64.0%) 15 (22.4%) Call -4 1.90 (55.4%) 1.05 (40.0%) 15 (22.4%) CFS 1-3 1.80 (55.4%) 1.80 (64.0%) 1.8 (26.9%) 0.001 Pre-vious episode of delin'um 37 (12.8%) 8 (3.6%)0		All patients	No delirium	Delirium	
Age (years)76 (68-82)74 (67-81)82 (77-86)<0.001		•			p-value
Ale (%) 238 (57.8%) 191 (57.9%) 47 (57.3%) 0.93 Body Mass index (kg/m ²) 2.62 (23.9-29.2) 2.63 (24.2-29.1) 2.51 (22.8-30.1) 0.06 Lving at home 363 (93.1%) 2.94 (94.8%) 6.9 (86.3%) 10.077 Lving at home 363 (93.1%) 2.94 (94.8%) 6.9 (86.3%) 11.03.7%) Charlson comorbidity index 2.67 (95.%) 16 (52.9%) 10.13.7%) 7.07 CCl 1-3 2.66 (79.1%) 2.65 (80.3%) 6.1 (77.3%) 7.01 CCl 1-4 7.4 (18.0%) 55 (16.7%) 19 (19.1%) 7.01 CCl 1-5 12 (2.9%) 10 (30.0%) 2.(3.6%) 7.01 CCl 1-4 7.4 (18.0%) 16 (5.6%) 18 (26.9%) 7.01 CCl 1-5 12 (2.9%) 10 (30.0%) 2.(3.6%) 7.01 CCl 1-5 12 (2.9%) 16 (3.0%) 15 (2.4%) 7.01 CFS 1-3 180 (55.4%) 16 (5.0%) 18 (2.6%) 7.01 CFS 4-5 6 (20.3%) 4 8 (18.6%) 3 (5 (5.0%) 7.00	Patient characteristics				
Bady Mass index (kg/m ²) 26.2 (23.9–29.2) 26.3 (24.2–29.1) 25.1 (22.8–30.1) 0.007 Living situation before admission 0.007 0.007 0.007 Living at home 363 (93.1%) 294 (94.8%) 69 (86.3%) 11 (13.7%) Nursing home 27 (6.9%) 16 (5.2%) 11 (13.7%) 0.007 Clarison comorbidity index - 0.4 0.007 CCl 1-3 226 (79.1%) 265 (80.3%) 11 (13.7%) CCl 1-4 74 (18.0%) 55 (16.57%) 19 (19.1%) - CCl 2-6 74 (18.0%) 165 (64.0%) 18 (26.9%) - CLinical frailty scale - - - - CFS 1-3 180 (55.4%) 165 (64.0%) 18 (26.9%) - CFS 4-5 66 (20.3%) 48 (18.6%) 18 (26.9%) - - Previous episode of delirium 70 (12.8%) 8 (36.%) 29 (45.3%) - - Previous episode of delirium 8 (29.2%) 48 (21.1%) 38 (55.9%) - - Use o	Age (years)	76 (68-82)	74 (67–81)	82 (77-86)	< 0.001
Living situation before admission0.007Living at home363 (93.1%)294 (94.8%)69 (86.3%)Nursing home27 (6.9%)16 (5.2%)11 (13.7%)Charlson comorbidity index27 (6.9%)265 (80.3%)61 (77.3%)CC1 1-3326 (79.1%)265 (80.3%)61 (77.3%)CC1 4-674 (18.0%)516 /3%)19 (19.1%)CC1 -512 (2.9%)10 (30.8%)19 (19.1%)CT5 1-3180 (55.4%)165 (44.0%)16 (22.4%)CF5 4-564 (20.3%)48 (18.4%)18 (26.9%)CF5 4-779 (24.3%)45 (17.4%)34 (50.8%)CF5 6-779 (24.3%)0 (0-2)3 (0-6)-0.01Previous episode of delirium0 (0-3)0 (0-2)3 (0-6)-0.01Previous episode of delirium66 (18.9%)2(17.9%)44 (62.0%)-0.01Previous episode of delirium66 (18.9%)2(17.9%)44 (62.0%)-0.01Previous episode of delirium66 (18.9%)2(17.9%)46 (73.0%)-0.01Previous episode of delirium61 (18.9%)2(17.9%)46 (73.0%)-0.01Use of epicodis18 (52.2%)16 (5.6%)2(3.3%)0.01Use of adoptication pre-saturements2(0.4%)16 (5.6%)2(3.3%)0.02Use of adoptication pre-saturements2(0.4%)16 (5.6%)2(3.3%)0.02Use of adoptication pre-saturements2(0.6%)16 (5.6%)2(3.3%)0.02Use of adoptication pre-saturements2(0.6%)16 (5.6%)2(3.3%)<	Male (%)	238 (57.8%)	191 (57.9%)	47 (57.3%)	0.93
Lung at home 363 (93.13%) 294 (94.88) 69 (86.3%) Nursing home 27 (6.9%) 16 (5.2%) 11 (13.7%) Charlson comorbidity index 27 (6.9%) 265 (80.3%) 61 (77.3%) CC1 1-3 326 (79.1%) 265 (80.3%) 61 (77.3%) CC1 4-6 74 (18.0%) 55 (16.7%) 19 (19.1%) CC1 5-6 12 (2.9%) 10 (3.0%) 2 (3.6%) CFS 1-3 180 (55.4%) 165 (64.0%) 18 (26.9%) CFS 4-5 66 (20.3%) 48 (18.6%) 18 (26.9%) CFS 4-5 66 (0.2%) 3 (0.0 3 (0.0 CFS 4-5 66 (18.9%) 18 (18.6%) 3 (0.6) <0.001	Body Mass index (kg/m²)	26.2 (23.9–29.2)	26.3 (24.2-29.1)	25.1 (22.8-30.1)	0.06
Nursing home27 (6.%)16 (5.%)11 (13.%)Charlson comorbidity index	Living situation before admission				0.007
Charlson comorbidity index 262 (79.1%) 265 (80.3%) 61 (77.3%) 4 CCI 1-3 74 (18.0%) 55 (16.7%) 19 (19.1%) 5 CCI 4-6 74 (18.0%) 50 (30.3%) 19 (19.1%) 5 CCI 5-6 12 (2.9%) 10 (30.0%) 2 (3.6%) 5 CFS 1-3 180 (55.4%) 145 (64.0%) 15 (22.4%) 5 CFS 4-5 66 (20.3%) 48 (18.6%) 18 (26.9%) 5 CFS 4-5 79 (24.3%) 45 (17.4%) 34 (50.3%) 4001 Previous episode of delinium 0 (0-3) 0 (0-2) 3 (0-6) 4001 Previous episode of delinium 37 (12.8%) 8 (3.6%) 29 (45.3%) 4001 Previous episode of delinium 66 (18.9%) 22 (7.9%) 44 (62.0%) 4001 Previous episode of delinium 8 (26.2%) 10 (20.5%) 6.001 6.001 Use of benzodiazepines 24 (6.9%) 20 (7.9%) 44 (62.0%) 0.001 Use of benzodiazepines 24 (6.9%) 20 (7.9%) 2(3.3%) 0.002 Use of benzodiazepines 24 (6.9%) 20 (7.0%) 2(3.3%)0	Living at home	363 (93.1%)	294 (94.8%)	69 (86.3%)	
CC1 1-3 262 (79.1%) 265 (80.3%) 61 (77.3%) CC1 4-6 74 (18.0%) 55 (16.7%) 19 (19.1%) CC1 5-6 12 (2.9%) 10 (3.0%) 2 (3.6%) CTinical frailty scale 12 (2.9%) 165 (64.0%) 15 (22.4%) CFS 1-3 66 (20.3%) 48 (18.6%) 18 (26.9%) CFS 4-5 64 (20.3%) 45 (17.4%) 34 (50.8%) CFS 6-9 79 (24.3%) 45 (17.4%) 34 (50.8%) Previous episode of delirium 0 (0-3) 0 (0-2) 3 (0-6) <0.01	Nursing home	27 (6.9%)	16 (5.2%)	11 (13.7%)	
CCI 4-6 74 (18.0%) 55 (16.7%) 19 (19.1%) CCI >6 12 (2.9%) 10 (3.0%) 2 (3.6%) CLinical frailty scale	Charlson comorbidity index				0.4
CCI >6 12 (2,9%) 10 (3,0%) 2 (3,6%) CLinical frailty scale -0.001 CF5 1-3 180 (55,4%) 165 (64,0%) 15 (22,4%) CF5 4-5 66 (20,3%) 48 (18,6%) 18 (26,9%) CF5 6-9 79 (24,3%) 45 (17,4%) 34 (50,8%) Katz-ADL 0 (0-3) 0 (0-2) 3 (0-6) <0.001	CCI 1-3	326 (79.1%)	265 (80.3%)	61 (77.3%)	
Clinical fraiity scale < < <	CCI 4-6	74 (18.0%)	55 (16.7%)	19 (19.1%)	
CFS 1-3180 (55.4%)165 (64.0%)15 (22.4%)CFS 4-566 (20.3%)48 (18.6%)18 (26.9%)Fato 5 6 -979 (24.3%)45 (17.4%)34 (50.8%)Katz-ADL0 (0-3)0 (0-2)3 (0-4)<0001	CCI >6	12 (2.9%)	10 (3.0%)	2 (3.6%)	
CFS 4-5 66 (20.3%) 48 (18.6%) 18 (26.9%) CFS 6-9 79 (24.3%) 45 (17.4%) 34 (50.8%) Katz-ADL 0 (0-3) 0 (0-2) 3 (0-6) <0001	Clinical frailty scale				<0.001
CFS 6-9 79 (24.3%) 45 (17.4%) 34 (50.8%) Katz-ADL 0 (0-3) 0 (0-2) 3 (0-6) <0001	CFS 1-3	180 (55.4%)	165 (64.0%)	15 (22.4%)	
Katz-ADL 0 (0-3) 0 (0-2) 3 (0-6) <0001 Previous episode of delirium 37 (12.8%) 8 (3.6%) 29 (45.3%) <0001	CFS 4-5	66 (20.3%)	48 (18.6%)	18 (26.9%)	
Previous episode of delirium 37 (12.8%) 8 (3.6%) 29 (45.3%) <0001 Pre-existent memory problems 66 (18.9%) 22 (7.9%) 44 (62.0%) <0001	CFS 6-9	79 (24.3%)	45 (17.4%)	34 (50.8%)	
Pre-existent memory problems 66 (18.9%) 22 (7.9%) 44 (62.0%) <0001	Katz-ADL	0 (0-3)	0 (0-2)	3 (0-6)	<0.001
Fall in the past 6 months 86 (29.2%) 48 (21.1%) 38 (55.9%) <0001 Use of medication pre-admission Use of benzodiazepines 24 (6.9%) 20 (7.0%) 4 (6.7%) 0.9 Use of pioids 18 (5.2%) 16 (5.6%) 2 (3.3%) 0.5 Use of haloperidol 2 (0.6%) 0 2 (3.3%) 0.002 Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0 Vital and laboratory measurements at admission 5 (1.7%) 3 (5%) 0.1 Systolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Diastolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 I biastolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 I biastolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 I coxy partici blood pressure (mmHg) 19 (69-88) 79 (70-88) 79 (66-88) 0.5 I coxy partici blood pressure (mmHg) 2 (0-4) 2 (0-3) 0.2	Previous episode of delirium	37 (12.8%)	8 (3.6%)	29 (45.3%)	<0.001
Use of medication pre-admission Use of benzodiazepines 24 (6.9%) 20 (7.0%) 4 (6.7%) 0.9 Use of opioids 18 (5.2%) 16 (5.6%) 2 (3.3%) 0.5 Use of haloperidol 2 (0.6%) 0 2 (3.3%) 0.002 Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.102 Vital and laboratory measurements at admission 5 (1.7%) 3 (5%) 0.1 Systolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Diastolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Quygen suppletion (L/min) 79 (69-88) 79 (70-88) 79 (66-88) 0.5 Quygen suppletion (L/min) 2 (0-4) 2 (0-3) 0.4 0.4 Oxygen suppletion (L/min) 2 (0-4) 2 (0-3) 0.2 0.2 Temperature 37.7 (37.0-38.5) 37.7 (37.0-38.4) 0.62 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	Pre-existent memory problems	66 (18.9%)	22 (7.9%)	44 (62.0%)	<0.001
Use of benzodiazepines 24 (6.9%) 20 (7.0%) 4 (6.7%) 0.9 Use of opioids 18 (5.2%) 16 (5.6%) 2 (3.3%) 0.5 Use of haloperidol 2 (0.6%) 0 2 (3.3%) 0.002 Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.102 Iso of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.102 Iso of atypical antipsychotics 138 (124-154) 138 (125-155) 3 (5 (119-153)) 0.4 Isolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Isolic blood pressure (mmHg) 19 (6-88) 79 (70-88) 19 (6-88) 0.4 Isolic blood pressure (mmHg) 2 (18-25) 2 (16-25) 0.4 Isolic blood pressure (mmHg) 2 (0-4) 2 (0-4) 2 (0-3) 0.2 Isolic blood pressure (mmHg) 2 (0.7 3.7 (37.0-38.5) 3.7 (37.0-38.5) 0.2 Isolic blood pressure (mmHg) 2 (0-4) 2 (0-4) 2 (0-3) 0.2 Isolic blood pressure (mmHg) 3.7 (37.0-38.5)<	Fall in the past 6 months	86 (29.2%)	48 (21.1%)	38 (55.9%)	< 0.001
Use of opioids 18 (5.2%) 16 (5.6%) 2 (3.3%) 0.5 Use of haloperidol 2 (0.6%) 0 2 (3.3%) 0.002 Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.1 Systolic blood pressure ments at admission 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Systolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Diastolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Instance (momHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Instance (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Instance (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Instance (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Instance (mmHg) 20 (16-25) 0.4 138 (124-154) 20 (0-4) 20-3) 0.2 Instance (mmHg) 20 (-4) 2 (0-4) 2 (0-3) 3.7 (37.0-38.4)	Use of medication pre-admission				
Use of haloperidol 2 (0.6%) 0 2 (3.3%) 0.002 Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.1 VI-Lat and laboratory measurements at admission 5 (1.7%) 3 (5%) 0.1 Systolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Diastolic blood pressure (mmHg) 79 (69-88) 79 (70-88) 79 (66-88) 0.5 Respiratory rate 21 (18-25) 21 (18-25) 20 (16-25) 0.4 Oxygen suppletion (L/min) 2 (0-4) 2 (0-3) 0.2 Temperature 37.7 (37.0-38.5) 37.7 (37.0-38.4) 0.6 Creatinine (µmol/L) 89 (72-123) 87 (71-118) 98 (75-134) 0.02 CRP (mg/L) 81 (38-132) 85 (39-139) 67 (30-107) 0.02	Use of benzodiazepines	24 (6.9%)	20 (7.0%)	4 (6.7%)	0.9
Use of atypical antipsychotics 8 (2.3%) 5 (1.7%) 3 (5%) 0.1 Vital and laboratory measurements at admission 5 (1.7%) 3 (5%) 0.1 Systolic blood pressure (mmHg) 138 (124-154) 138 (125-155) 136 (119-153) 0.4 Diastolic blood pressure (mmHg) 79 (69-88) 79 (70-88) 79 (66-88) 0.5 Respiratory rate 21 (18-25) 21 (18-25) 20 (16-25) 0.4 Oxygen suppletion (L/min) 2 (0-4) 2 (0-3) 0.2 Temperature 37.7 (37.0-38.5) 37.7 (37.0-38.4) 0.6 Creatinine (µmol/L) 89 (72-123) 87 (71-118) 98 (75-134) 0.02 CRP (mg/L) 81 (38-132) 85 (39-139) 67 (30-107) 0.03	Use of opioids	18 (5.2%)	16 (5.6%)	2 (3.3%)	0.5
Vital and laboratory measurements at admission Systolic blood pressure (mmHg) 138 (124–154) 138 (125–155) 136 (119–153) 0.4 Diastolic blood pressure (mmHg) 79 (69–88) 79 (70–88) 79 (66–88) 0.5 Respiratory rate 21 (18–25) 21 (18–25) 20 (16–25) 0.4 Oxygen suppletion (L/min) 2 (0–4) 2 (0–4) 2 (0–3) 0.2 Temperature 37.7 (37.0–38.5) 37.7 (37.0–38.5) 37.7 (37.0–38.4) 0.6 Creatinine (µmol/L) 89 (72–123) 87 (71–118) 98 (75–134) 0.02 CRP (mg/L) 81 (38–132) 85 (39–139) 67 (30–107) 0.008	Use of haloperidol	2 (0.6%)	0	2 (3.3%)	0.002
Systolic blood pressure (mmHg)138 (124-154)138 (125-155)136 (119-153)0.4Diastolic blood pressure (mmHg)79 (69-88)79 (70-88)79 (66-88)0.5Respiratory rate21 (18-25)21 (18-25)20 (16-25)0.4Oxygen suppletion (L/min)2 (0-4)2 (0-4)2 (0-3)0.2Temperature37.7 (37.0-38.5)37.7 (37.0-38.5)37.7 (37.0-38.4)0.64Creatinine (µmol/L)89 (72-123)87 (71-118)98 (75-134)0.02CRP (mg/L)81 (38-132)85 (39-139)67 (30-107)0.008	Use of atypical antipsychotics	8 (2.3%)	5 (1.7%)	3 (5%)	0.1
Diastolic blood pressure (mmHg)79 (69-88)79 (70-88)79 (66-88)0.5Respiratory rate21 (18-25)21 (18-25)20 (16-25)0.4Oxygen suppletion (L/min)2 (0-4)2 (0-4)2 (0-3)0.2Temperature37.7 (37.0-38.5)37.7 (37.0-38.5)37.7 (37.0-38.4)0.6Creatinine (µmol/L)89 (72-123)87 (71-118)98 (75-134)0.02CRP (mg/L)81 (38-132)85 (39-139)67 (30-107)0.098	Vital and laboratory measurements at admission				
Respiratory rate21 (18–25)21 (18–25)20 (16–25)0.4Oxygen suppletion (L/min)2 (0–4)2 (0–4)2 (0–3)0.2Temperature37.7 (37.0–38.5)37.7 (37.0–38.4)0.6Creatinine (µmol/L)89 (72–123)87 (71–118)98 (75–134)0.02CRP (mg/L)81 (38–132)85 (39–139)67 (30–107)0.008	Systolic blood pressure (mmHg)	138 (124–154)	138 (125–155)	136 (119–153)	0.4
Oxygen suppletion (L/min)2 (0-4)2 (0-3)0.2Temperature37.7 (37.0-38.5)37.7 (37.0-38.4)0.6Creatinine (µmol/L)89 (72-123)87 (71-118)98 (75-134)0.02CRP (mg/L)81 (38-132)85 (39-139)67 (30-107)0.098	Diastolic blood pressure (mmHg)	79 (69–88)	79 (70-88)	79 (66-88)	0.5
Temperature37.7 (37.0-38.5)37.7 (37.0-38.5)37.7 (37.0-38.4)0.6Creatinine (μmol/L)89 (72-123)87 (71-118)98 (75-134)0.02CRP (mg/L)81 (38-132)85 (39-139)67 (30-107)0.008	Respiratory rate	21 (18–25)	21 (18-25)	20 (16-25)	0.4
Creatinine (μmol/L)89 (72-123)87 (71-118)98 (75-134)0.02CRP (mg/L)81 (38-132)85 (39-139)67 (30-107)0.008	Oxygen suppletion (L/min)	2 (0-4)	2 (0-4)	2 (0-3)	0.2
CRP (mg/L) 81 (38-132) 85 (39-139) 67 (30-107) 0.008	Temperature	37.7 (37.0-38.5)	37.7 (37.0-38.5)	37.7 (37.0-38.4)	0.6
	Creatinine (µmol/L)	89 (72-123)	87 (71–118)	98 (75-134)	0.02
Duration of symptoms pre-admission (days) 7 (4-10) 7 (5-11) 4 (2-7) <0.001	CRP (mg/L)	81 (38-132)	85 (39–139)	67 (30-107)	0.008
	Duration of symptoms pre-admission (days)	7 (4-10)	7 (5-11)	4 (2-7)	<0.001

Missing data: 71 BMI, 22 living situation before admission, 87 CFS, 103 KATZ-ADL, 123 previous episode of confusion, 63 pre-existent memory problems, 117 falling in the past six months, 65 use of benzodiazepines, 65 use of opioids, 65 use of haloperidol, 65 use of atypical antipsychotics, one systolic blood pressure, one diastolic blood pressure, six respiratory rate, 64 oxygen suppletion, two temperature, nine creatinine, eight CRP, 35 duration of symptoms pre-admission.

Abbreviations: ADL, activities of daily living; CI, Confidence interval; CCI, Charlson Comorbidity Index; CRP, C-reactive protein; KATZ-ADL, Katz-Activities of daily living; OR, Odds ratio.

delirium.¹⁹ However, differences in study population, covariates included and CFS cut-off values used make these results not directly comparable to our findings. Our results emphasize that, in addition to

frailty, it is important to assess cognitive impairment and the occurrence of a prior delirious episode to establish delirium risk in COVID-19 patients.

	Crude		Multivariable	
Determinants	OR (95% CI)	p-value	OR (95% CI)	p-value
Age (years)	1.10 (1.07-1.14)	<0.001	1.02 (0.97-1.10)	0.5
Previous episode of delirium	22.5 (9.5-53.1)	<0.001	8.9 (2.3-33.6)	0.001
History of memory problems	19.0 (9.9-36.2)	< 0.001	7.6 (3.1-22.5)	< 0.001
Charlson comorbidity index (continuous)	1.14 (1.02-1.28)	0.026	0.94 (0.72-1.2)	0.6
ADL dependency (continuous)	1.45 (1.28-1.64)	<0.001	1.01 (0.78-1.32)	0.3
Fall in the last 6 month	4.7 (2.7-8.4)	<0.001	1.44 (0.53–3.91)	0.5
CFS score (continuous)	1.63 (1.40-1.90)	<0.001	1.20 (0.88-1.63)	0.3

Note: The crude analyses of the individual determinants are presented in the left column. The multivariable analysis is presented in the right column. This multivariable model included all the determinant, adjusted for sex.

Abbreviations: ADL, activities of daily living; CFS, clinical frailty scale; CI, Confidence interval; OR, Odds ratio.

	Crude	Crude		Multivariable	
	OR (95% CI)	p-value	OR (95% CI)	p-value	
Age (years)	1.09 (1.06-1.12)	< 0.001	1.04 (1.01-1.08)	0.012	
Delirium	2.84 (1.71-4.72)	<0.001	1.11 (0.57–2.18)	0.8	
Charlson comorbidity index	1.22 (1.09-1.36)	< 0.001	1.10 (0.95-1.27)	0.2	
CFS score (continuous)	1.48 (1.29-1.70)	<0.001	1.42 (1.20-1.67)	<0.001	

TABLE 3Determinants of in-hospital mortality in COVID-19

TABLE 2 Predisposing determinants

of delirium

Note: The crude analyses of the individual determinants are presented in the left column. The multivariable analysis is presented in the right column. This multivariable model included all the determinant, adjusted for sex.

Abbreviations: CFS, Clinical Frailty Scale; CI, Confidence Interval; OR, Odds Ratio.

	Delirium ($n = 82$)	No delirium ($n = 330$)	p-value
Length of stay (days)	8 (5-13)	6 (3-10)	0.002
Destination at discharge			0.001
- Home ^a	29 (64.4%)	217 (84.8%)	
- Nursing home ^b	16 (35.6%)	39 (15.2%)	
In-hospital mortality	37 (45.1%)	74 (22.4%)	<0.001

TABLE 4In-hospital outcomes inpatients with and without delirium

Note: Data are presented as number (with percentage), or as median (with interquartile range). *N*, number. Destination at discharge.

^aWith or without homecare.

^bNursing home admission could be temporarily or permanent.

Patients who developed a delirium had worse in-hospital outcomes. In our study, the in-hospital mortality of patients with a delirium in our study was doubled compared to the non-delirious patients. This result is in accordance with a recent study that reported a pooled mortality rate of 44.5% in COVID-19 patients who developed a delirium,³³ and with a recent review that described a higher risk of mortality in patients with COVID-19 who developed a delirium.³⁴

There is conflicting evidence whether delirium and frailty are both independent predictors of in-hospital mortality. For instance Garcez

et al. found delirium to be an independent predictor of mortality in COVID-19 patients aged 50 years and older.³⁵ Furthermore other studies also found that delirium is an independent predictor of mortality.²¹⁻²³ Others, on the contrary, found CFS to be a predictor of mortality and not delirium.^{19,24} Our findings suggest that frailty might be a better predictor for in-hospital mortality than delirium, although in light of the contradicting evidence, further study is needed to examine the complex interaction between frailty and delirium.

This study also found that patients who developed a delirium had lower CRP levels and lower duration of symptoms at baseline, whereas there was no difference in vital signs. These findings seem to suggest that predisposing delirium risk factors, for example, a previous delirium, are more important than precipitating delirium risk factors, for example, disease severity at presentation, for delirium risk in COVID-19 patients.

Our study has some limitations. First, data were collected in the first wave of the COVID-19 pandemic, when there were no disease specific treatments or vaccinations available, leading to worse inhospital outcomes. However, risk factors for delirium and the underlying biological vulnerability for delirium are still present today in older hospitalized patients with COVID-19. A recent study reported similar delirium prevalence in both the first and second COVID wave (23.4% vs. 23.2%). Thus, despite the developments in therapy the rate of delirium remained similar, while outcomes like mortality improved in the second wave.³⁶ Second. CFS data were partly collected retrospectively. This might introduce classification bias, as the assessor was not blinded for the presence of delirium and for the in-hospital outcomes. Nevertheless, a recent study has shown a good correlation between the CFS when assessed prospectively and retrospectively, therefore we are confident that our information on CFS is correct.³⁷ Third, we excluded patients who were transferred to the ICU thereby reducing the delirium prevalence in our cohort, possibly introducing selection bias. Nevertheless, we specifically chose to exclude those patients due to different sedation strategies in the various hospitals, leading to a large difference in rating of 'delirium days' and 'comatose days' at ICU's of the various hospitals. Fourth, our study included only patients from the Netherlands, thereby limiting the generalizability especially to non-western countries. For the analysis of delirium risk factors, it must be recognized that there may be a correlation and thus some overlap between the individual delirium risk factors. As an example (I)ADL dependence is also reflected in the CFS score. The multivariable model revealed which risk factors are most strongly associated.

There are also strengths to our study. Data were collected from different hospitals from various regions in the Netherlands including a heterogeneous patient population. Furthermore, geriatric parameters were prospectively collected using the Dutch National Safety Management System. As a result, we collected representative data that are easily translatable to clinical practice.

The findings of our study raise awareness of delirium risk and underscore the importance of screening for delirium risk factors in older hospitalized COVID-19 patients. Delirium is associated with longer hospital stay, discharge to a nursing home, and higher mortality. However, early recognition of patients at risk for delirium may improve outcomes since preventive strategies on the management of delirium have shown to reduce the incidence of delirium by 40%.^{38,39} Besides prevention, early recognition of delirium is important for appropriate treatment in order to reduce the length and severity of a delirium. Further research is needed to investigate the effects of delirium on other in hospital outcomes like in-hospital falls and long term outcomes in older patients with COVID-19, for instance cognitive function and independency. In conclusion, a previous delirium and pre-existent memory problems were associated with delirium in COVID-19. Delirium was not an independent predictor of mortality after adjustment for frailty.

Our findings stress the importance of assessing predisposing risk factors for delirium in addition to frailty in older patients hospitalized with COVID-19.

AUTHOR CONTRIBUTIONS

Jessica M. van der Bol, Jan Festen, Steffy W. M. Jansen, Carolien J. M. van der Linden, Simon P. Mooijaart, Hanna C. Willems, Harmke A. Polinder-Bos designed the COVID-OLD study. Bart Kroon, Sara J. E. Beishuizen, Harmke A. Polinder-Bos, Francesco U. S. Mattace-Raso developed the research question and analysis plan. Simon P. Mooijaart, Carolien J. M. van der LindenL, Harmke A. Polinder-Bos, Francesco U. S. Mattace-Raso, Hanna C. Willems obtained research funding. Bart Kroon, Inge H. T. van Rensen, Dennis G. Barten, Jannet J. Mehagnoul-Schipper, Jessica M. van der Bol, Jacobien L. J. Ellerbroek, Esther M. M. van de Glind, Liesbeth Hempenius, Mathieu van der Jagt, Steffy W. M. Jansen, Carolien J. M. van der Linden, Simon P. Mooijaart, Barbara C. van Munster, BO, Lisa Smit, Louise C. Urlings-Strop, Hanna C. Willems, Harmke A. Polinder-Bos obtained research data. Bart Kroon conducted data analysis and interpretation with oversight by Sara J. E. Beishuizen, Francesco U. S. Mattace-Raso, Harmke A. Polinder-Bos. Bart Kroon and Sara J. E. Beishuizen co-wrote the manuscript and all other authors provided critical feedback on the manuscript.

ACKNOWLEDGEMENTS

This work was supported by Zorg Onderzoek Nederland en Medische Wetenschappen (ZonMw) to the COVID-19 Outcomes in Older People (COOP) study (project number 10430102110005) under the COVID-19 program. ZonMW had no role in data analysis or reporting.

CONFLICT OF INTEREST

None or the authors reported a conflict of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

IMPACT STATEMENT

We certify that this work is novel. It is one of the few studies that investigates frailty as a predictor of delirium independent of traditional predisposing delirium risk factors. It also sheds new light on the debate whether delirium and frailty are both independent predictors of mortality in older COVID-19 patients.

WHY DOES THIS PAPER MATTER?

A high incidence of delirium has been reported in older patients with COVID-19. Patients with delirium have been known to have worse outcomes. Therefore it is important to identify which patients are at

⁸ WILEY Geriatric Psychiatr

risk for delirium. Our findings emphasize that, in addition to frailty, it is important to assess pre-existent cognitive impairment and the occurrence of a previous delirium to establish delirium risk in older patients admitted for COVID-19.

ORCID

Bart Kroon () https://orcid.org/0000-0003-0235-3355

REFERENCES

- Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. *Lancet Public Health*. 2020;5(8): e444-e451. https://doi.org/10.1016/S2468-2667(20)30146-8
- Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020;80(6):e14-e18. https://doi.org/10.1016/j.jinf.2020.03. 005. S0163-4453(20)30116-X [pii].
- Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775-1776. https://doi.org/10.1001/jama.2020.4683. 2763667 [pii].
- Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. J Clin Med. 2020;9(4). https://doi.org/10.3390/ jcm9040941
- Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-tomoderate coronavirus disease 2019. J Intern Med. 2020;288(3): 335-344. https://doi.org/10.1111/joim.13089
- Kennedy M, Helfand BKI, Gou RY, et al. Delirium in older patients with COVID-19 presenting to the emergency department. JAMA Netw Open. 2020;3(11):e2029540. https://doi.org/10.1001/ jamanetworkopen.2020.29540. 2773106 [pii].
- Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a metaanalysis. JAMA. 2010;304(4):443-451. https://doi.org/10.1001/ jama.2010.1013. 304/4/443 [pii].
- Marcantonio ER. Delirium in hospitalized older adults. N Engl J Med. 2017;377(15):1456-1466. https://doi.org/10.1056/NEJMcp1 605501
- Hawkins M, Sockalingam S, Bonato S, et al. A rapid review of the pathoetiology, presentation, and management of delirium in adults with COVID-19. J Psychosom Res. 2021;141:110350. https://doi.org/10.1016/j.jpsychores.2020.110350. S0022-3999(20) 30912-0 [pii].
- Low B, Xian NQ, Brooks I, Heller A, Daher B, Dani M. Delirium in older inpatients with COVID-19: impact on service provision. *Future Healthc J.* 2021;8(3):e689-e691. https://doi.org/10.7861/fhj.2021-0017. futurehealth [pii].
- Rebora P, Rozzini R, Bianchetti A, et al. Delirium in patients with SARS-CoV-2 infection: a multicenter study. J Am Geriatr Soc. 2021;69(2):293-299. https://doi.org/10.1111/jgs.16969
- Dasgupta M, Brymer C. Prognosis of delirium in hospitalized elderly: worse than we thought. Int J Geriatr Psychiatr. 2014;29(5):497-505. https://doi.org/10.1002/gps.4032
- Gual N, Morandi A, Perez LM, et al. Risk factors and outcomes of delirium in older patients admitted to postacute care with and without dementia. *Dement Geriatr Cognit Disord*. 2018;45(1-2):121-129. https://doi.org/10.1159/000485794
- Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383(9920):911-922. https://doi.org/10.1016/S0140-6736(13)60688-1

- Ahmed S, Leurent B, Sampson EL. Risk factors for incident delirium among older people in acute hospital medical units: a systematic review and meta-analysis. *Age Ageing*. 2014;43(3):326-333. https:// doi.org/10.1093/ageing/afu022
- Andres-Esteban EM, Quintana-Diaz M, Ramirez-Cervantes KL, et al. Outcomes of hospitalized patients with COVID-19 according to level of frailty. *PeerJ*. 2021;9:e11260. https://doi.org/10.7717/peerj. 11260
- Dumitrascu F, Branje KE, Hladkowicz ES, Lalu M, McIsaac DI. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021;69(9): 2419-2429. https://doi.org/10.1111/jgs.17299
- Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021;93:104324. https:// doi.org/10.1016/j.archger.2020.104324. S0167-4943(20)30321-6 [pii].
- Geriatric Medicine Research C, Covid C, Welch C. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multicentre study. *Age Ageing*. 2021;50(3):617-630. https://doi.org/10. 1093/ageing/afab026. 6128535 [pii].
- Shao SC, Lai CC, Chen YH, Chen YC, Hung MJ, Liao SC. Prevalence, incidence and mortality of delirium in patients with COVID-19: a systematic review and meta-analysis. *Age Ageing*. 2021. https://doi. org/10.1093/ageing/afab103. 6274714 [pii].
- Marengoni A, Zucchelli A, Grande G, Fratiglioni L, Rizzuto D. The impact of delirium on outcomes for older adults hospitalised with COVID-19. Age Ageing. 2020;49(6):923-926. https://doi.org/10. 1093/ageing/afaa189. 5894896 [pii].
- Callea A, Conti G, Fossati B, et al. Delirium in hospitalized patients with COVID-19 pneumonia: a prospective, cross-sectional, cohort study. *Intern Emerg Med.* 2022. https://doi.org/10.1007/s11739-022-02934-w
- Knopp P, Miles A, Webb TE, et al. Presenting features of COVID-19 in older people: relationships with frailty, inflammation and mortality. *Eur Geriatr Med.* 2020;11(6):1089-1094. https://doi.org/10. 1007/s41999-020-00373-4
- De Smet R, Mellaerts B, Vandewinckele H, et al. Frailty and mortality in hospitalized older adults with COVID-19: retrospective observational study. J Am Med Dir Assoc. 2020;21(7):928-932.e1. https://doi. org/10.1016/j.jamda.2020.06.008. S1525-8610(20)30514-4 [pii].
- VMS Praktijkgids 'Kwetsbare Ouderen'. Den Haag: VMS Veiligheidsprogramma; 2009. https://www.vmszorg.nl/wp-content/uploads/ 2017/11/web_2009.0104_praktijkgids_kwetsbare_ouderen.pdf
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373-383. https://doi. org/10.1016/0021-9681(87)90171-8
- Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The Index of Adl: a standardized measure of biological and Psychosocial function. JAMA. 1963;185(12):914-919. https://doi.org/10.1001/jama.1963.03060120024016
- Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ (Can Med Assoc J). 2005;173(5):489-495. https://doi.org/10.1503/cmaj.050051. 173/5/ 489 [pii].
- Schuurmans MJ, Shortridge-Baggett LM, Duursma SA. The delirium observation screening scale: a screening instrument for delirium. *Res Theor Nurs Pract*. 2003;17(1):31-50. https://doi.org/10.1891/rtnp.17. 1.31.53169
- Williamson CA, Faiver L, Nguyen AM, Ottenhoff L, Rajajee V. Incidence, predictors and outcomes of delirium in critically ill patients with COVID-19. Neurohospitalist. 2022;12(1):31-37. https://doi.org/ 10.1177/19418744211034815

- Mendes A, Herrmann FR, Perivier S, Gold G, Graf CE, Zekry D. Delirium in older patients with COVID-19: prevalence, risk factors, and clinical relevance. J Gerontol A Biol Sci Med Sci. 2021;76(8):e142-e146. https://doi.org/10.1093/gerona/glab039. 6128716 [pii].
- Zhang XM, Jiao J, Xie XH, Wu XJ. The association between frailty and delirium among hospitalized patients: an updated meta-analysis. J Am Med Dir Assoc. 2021;22(3):527-534. https://doi.org/10.1016/j. jamda.2021.01.065. S1525-8610(21)00115-8 [pii].
- Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. *Lancet Respir Med.* 2021;9(3):239-250. https://doi.org/10.1016/S2213-2600(20)30552-X. S2213-2600(20) 30552-X [pii].
- Pranata R, Huang I, Lim MA, Yonas E, Vania R, Kuswardhani RAT. Delirium and mortality in coronavirus disease 2019 (COVID-19) - a systematic review and meta-analysis. Arch Gerontol Geriatr. 2021;95:104388. https://doi.org/10.1016/j.archger.2021.104388. S0167-4943(21)00051-0 [pii].
- Garcez FB, Aliberti MJR, Poco PCE, et al. Delirium and adverse outcomes in hospitalized patients with COVID-19. J Am Geriatr Soc. 2020;68(11):2440-2446. https://doi.org/10.1111/jgs.16803

- 36. Blomaard LC, van der Linden CMJ, van der Bol JM, et al. Frailty is associated with in-hospital mortality in older hospitalised COVID-19 patients in The Netherlands: the COVID-OLD study. Age Ageing. 2021;50(3):631-640. https://doi.org/10.1093/ageing/ afab018. 6265118 [pii].
- Stille K, Temmel N, Hepp J, Herget-Rosenthal S. Validation of the Clinical Frailty Scale for retrospective use in acute care. *Eur Geriatr Med.* 2020;11(6):1009-1015. https://doi.org/10.1007/s41999-020-00370-7
- Rieck KM, Pagali S, Miller DM. Delirium in hospitalized older adults. Hosp Pract. 2020;48(Suppl 1):3-16.(1995). https://doi.org/10.1080/ 21548331.2019.1709359
- 39. Faught DD. Delirium: the nurse's role in prevention, diagnosis, and treatment. *Medsurg Nurs.* 2014;23(5):301-305.

How to cite this article: Kroon B, Beishuizen SJE, van Rensen IHT, et al. Delirium in older COVID-19 patients: evaluating risk factors and outcomes. *Int J Geriatr Psychiatry*. 2022;1-9. https://doi.org/10.1002/gps.5810